Understand macular degeneration treatment options: An analysis of current clinical approaches and emerging therapies

Age-related macular degeneration (AMD) represents a leading cause of permanent, irreversible central vision loss among individuals aged 50 and older 2. Understanding the available treatment options is critical for patients and caregivers as management strategies diverge significantly depending on the clinical presentation, which is categorized primarily into dry and wet forms 1, 3. While no universal cure currently exists to restore lost vision, modern therapeutic advances focus on slowing disease progression, preserving existing visual function, and managing the physiological complications associated with the disease 3, 6.

Management of Dry Age-Related Macular Degeneration

Dry AMD, or nonexudative AMD, is the most prevalent form of the condition, affecting approximately 80 to 85 percent of all patients diagnosed with the disease 1, 2. It is characterized by the gradual breakdown of light-sensitive cells in the macula and the accumulation of deposits known as drusen 1, 4. For intermediate stages of dry AMD, clinical guidance often suggests the use of specialized nutritional supplements, specifically the AREDS2 formulation 2, 5. Research indicates these supplements may reduce the risk of progression to advanced stages in certain patient populations 5.

The AREDS2 formula is specifically engineered to replace beta-carotene with lutein and zeaxanthin General Information. This modification is clinically relevant for individuals who smoke or have a history of smoking, as beta-carotene has been associated with an increased risk of lung cancer in these groups General Information. It is important to note that while these supplements support nutritional health, they do not restore vision already lost to the condition, nor do they prevent the initial onset of the disease General Information.

Therapies for Geographic Atrophy

A significant, advanced manifestation of dry AMD is geographic atrophy, which involves the loss of retinal cells and results in central vision impairment 4. Until recently, options for this condition were primarily supportive. However, the regulatory landscape has evolved with the approval of complement-inhibitor therapies, such as pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay) General Information. These treatments are administered via intravitreal injection and are designed to slow the growth of geographic atrophy lesions General Information.

The application of these agents requires careful clinical oversight due to associated ocular and systemic risks. Potential adverse events identified in clinical documentation include increased intraocular pressure, the development of ocular inflammation, the risk of endophthalmitis, and a potential for conversion to the neovascular or wet form of the disease General Information. Patients undergoing these treatments are typically monitored closely by their ophthalmologists to balance the goal of lesion stabilization against the inherent risks of the injection procedure 5.

Clinical Protocols for Wet Age-Related Macular Degeneration

Wet AMD occurs when abnormal, leaky blood vessels form beneath the retina, often leading to rapid and severe vision loss 1, 6. The primary first-line intervention for this condition is the administration of anti-vascular endothelial growth factor (anti-VEGF) medications 8, 9. These agents block the protein responsible for the abnormal growth of blood vessels, effectively reducing retinal fluid and stabilization of the visual field in a significant majority of patients 6, 8.

Treatment schedules for anti-VEGF therapy are highly individualized, typically ranging from every four to 16 weeks based on patient response, with some newer protocols aiming for extended intervals 9. While these drugs are highly effective in preserving vision, the necessity for repeated intravitreal injections carries inherent risks, including post-injection endophthalmitis or retinal detachment 5, 9. Ongoing research is focused on developing more durable therapies to reduce the frequency of clinical visits while maintaining visual stability 6.

Historical and Alternative Interventions

While anti-VEGF injections currently dominate the clinical approach to wet AMD, other interventions are utilized in specific cases. Photodynamic therapy (PDT) with verteporfin involves the use of a light-activated drug to target abnormal blood vessels, while thermal laser photocoagulation may be considered for selected lesions that are not responsive to or suitable for injection therapy 2, General Information. These methods are generally less common than injection-based protocols but remain part of the ophthalmologist's broader therapeutic toolkit.

Emerging approaches, including gene therapy and small-molecule tyrosine kinase inhibitors (TKIs), are currently under investigation to address the limitations of existing treatments 9. Researchers aim to create solutions that might eventually offer longer-term suppression of neovascularization, potentially reducing the reliance on periodic, repeated injections. As of 2026, clinical practice continues to prioritize established anti-VEGF protocols while evaluating the long-term safety and efficacy profiles of these emerging alternatives 5, 9.

Low-Vision Rehabilitation and Lifestyle Management

Because AMD can result in permanent loss of central vision, management extends beyond medical procedures to include comprehensive low-vision rehabilitation 2, 8. Occupational therapy, the use of specialized magnifiers, and the adoption of adaptive technologies are essential components for maintaining patient independence General Information. These tools help individuals navigate daily tasks such as reading and recognizing faces, even when central vision is significantly compromised 1, 8.

Lifestyle modifications are also frequently recommended to support overall ocular health. These include smoking cessation, the management of systemic health conditions such as hypertension and high cholesterol, and the adoption of a diet rich in dark green leafy vegetables and omega-3 fatty acids 2, 3, General Information. Patients are encouraged to monitor their vision using tools like the Amsler grid and to seek immediate professional assessment if they notice new distortions, blank spots, or rapid declines in vision, as timely intervention is crucial in the wet form of the disease 3, General Information.

Regulatory Oversight and Clinical Considerations

The treatment of AMD is subject to rigorous regulatory standards and practice guidelines, such as those provided by the American Academy of Ophthalmology (AAO) and the European Society of Retina Specialists (EURETINA) 5. These bodies emphasize the importance of early detection and evidence-based decision-making. Physicians balance the patient's individual health history, the severity of retinal damage, and tolerance for ocular procedures when determining the appropriate course of action 5, General Information.

The shift toward personalized medicine in ophthalmology means that treatment decisions are rarely uniform. The choice of a specific biologic agent or the timing of an injection is often a collaborative decision between the ophthalmologist and the patient 5. Given the progressive nature of the disease, long-term adherence to follow-up schedules is necessary to maximize the durability of therapeutic outcomes and to mitigate potential complications associated with either the condition itself or its medical interventions 5, 9.

Sources

1. Johns Hopkins Medicine: Age-Related Macular Degeneration (AMD)
2. Merck Manual Professional Edition: Age-Related Macular Degeneration
3. Merck Manual Consumer Version: Age-Related Macular Degeneration
4. American Academy of Ophthalmology: Understanding Macular Degeneration
5. Healio: Treatment Guidelines for Age-Related Macular Degeneration
6. American Academy of Ophthalmology: New Treatments for Age-Related Macular Degeneration
7. Mayo Clinic Press: Geographic Atrophy Treatment Advances
8. American Academy of Ophthalmology: Anti-VEGF Treatments
9. Healio: Wet AMD Treatment